Gastrointestinal Infection Articles & Analysis
9 news found
SER-155 is designed using microbiome biomarker data from human clinical data, human cell-based assays, and in vivo disease models, with the aim to decrease infection and translocation of antibiotic-resistant bacteria in the gastrointestinal tract and modulate host immune responses to decrease GvHD. The rationale for this program is based in part on published ...
“These results suggest that our investigational microbiome therapeutic, SER-109, is a potentially fast-acting intervention that can provide durable relief from recurrent C. difficile infections when administered to vulnerable patients,” said Matthew Henn, Ph.D., Chief Scientific Officer at Seres. ...
SER-155 is designed using microbiome biomarker data from human clinical data, human cell-based assays, and in vivo disease models, with the aim to decrease infection and translocation of antibiotic-resistant bacteria in the gastrointestinal tract and modulate host immune responses to decrease GvHD. The rationale for this program is based in part on published ...
SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrentC. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the functionality of the microbiome in a rapid and durable manner, which further supports the potential of microbiome therapeutics. ...
SER-155 is an investigational oral, rationally designed, cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bloodstream infections, and GvHD in patients receiving allo-HSCT. ...
This includes GLUCOSAVE® a patient safety solution designed to help reduce the risk of a glucose solution being erroneously attached to an arterial line and ENDOVAC™ which applies the principles of negative pressure wound therapy internally to holes in the Upper Gastrointestinal Tract thus removing sources of infection and promoting healing. ...
ByMedovate
Founded in 1995, Hansoh has fully integrated research and development, manufacturing, and commercial capabilities, supporting a leadership position in oncology, central nervous system (CNS), anti-infectives, gastrointestinal disorders, diabetes, and autoimmune diseases, among others. ...
Noroviruses can cause severe gastrointestinal illness in infected people. According to the California Department of Public Health (CDPH), “People get a norovirus infection directly from an ill individual who did not wash his hands adequately, or indirectly from food or water contaminated by the stool or vomit from an ...
OptoLabCard, a project funded by the EU to the tune of over EUR 3 million, offers to not only protect the health and well-being of millions of Europeans but also to save hundreds of millions of euros spent treating gastrointestinal infections. Currently there is no simple and easy way to detect infectious bacteria at either farms or in the food processing and ...